184 related articles for article (PubMed ID: 33104795)
21. Risk Factors and Prediction Models for Venous Thromboembolism in Ambulatory Patients with Lung Cancer.
Yan AR; Samarawickrema I; Naunton M; Peterson GM; Yip D; De Rosa S; Mortazavi R
Healthcare (Basel); 2021 Jun; 9(6):. PubMed ID: 34205695
[TBL] [Abstract][Full Text] [Related]
22. Primary Thromboprophylaxis in Ambulatory Cancer Patients: Where Do We Stand?
Mulder FI; Bosch FTM; van Es N
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32033438
[TBL] [Abstract][Full Text] [Related]
23. Development and Validation of a Modified Khorana Score for Predicting Venous Thromboembolism in Newly Diagnosed Stage IV Lung Cancer.
Qin Y; Liang X; Wu H; Sun X; Yan S; Wang N; Yuan M; Wang Q; Wu D
Angiology; 2023 Nov; ():33197231213197. PubMed ID: 37924222
[TBL] [Abstract][Full Text] [Related]
24. Ability of the Khorana score to predict recurrent thromboembolism in cancer patients with ischemic stroke.
Murthy SB; Cushman M; Bobrow D; Kamel H; Merkler AE; Elkind MSV; DeAngelis LM; Navi BB
J Clin Neurosci; 2018 Nov; 57():111-115. PubMed ID: 30145085
[TBL] [Abstract][Full Text] [Related]
25. Biomarker risk assessment model identified high-risk patients with cancer who benefit from thromboprophylaxis.
van Zanten SV; Ritchie B
Ann Intern Med; 2024 Feb; 177(2):JC22. PubMed ID: 38315999
[TBL] [Abstract][Full Text] [Related]
26. Primary Thromboprophylaxis in People With Cancer-Where Next?
Khorana AA
JAMA Oncol; 2023 Nov; 9(11):1545-1546. PubMed ID: 37733351
[No Abstract] [Full Text] [Related]
27. Association between the Khorana risk score and all-cause mortality in Japanese patients with gastric and colorectal cancer: A retrospective cohort study.
Zhang YF; Wang GD; Huang MG; Qiu ZQ; Si J; Xu MY
World J Gastrointest Oncol; 2023 Oct; 15(10):1784-1795. PubMed ID: 37969412
[TBL] [Abstract][Full Text] [Related]
28. Non-vitamin K antagonist oral anticoagulants for stroke prevention in atrial fibrillation: safety issues in the elderly.
Ajam T; Cumpian TL; Tilkens BL; Jahangir IA; Frost J; Ceretto C; Jahangir A
Expert Rev Clin Pharmacol; 2020 Dec; 13(12):1309-1327. PubMed ID: 33107345
[TBL] [Abstract][Full Text] [Related]
29. Safety and effectiveness of biosimilar enoxaparin (Inhixa) for the prevention of thromboembolism in medical and surgical inpatients.
Fantoni C; Bertù L; Faioni EM; Froiio C; Mariani N; Ageno W
Intern Emerg Med; 2021 Jun; 16(4):933-939. PubMed ID: 33108640
[TBL] [Abstract][Full Text] [Related]
30. Venous thromboembolism in cancer patients: a population-based cohort study.
Mulder FI; Horváth-Puhó E; van Es N; van Laarhoven HWM; Pedersen L; Moik F; Ay C; Büller HR; Sørensen HT
Blood; 2021 Apr; 137(14):1959-1969. PubMed ID: 33171494
[TBL] [Abstract][Full Text] [Related]
31. Prevention and treatment of cancer-associated thrombosis.
Ng S; Carrier M
Curr Oncol; 2020 Oct; 27(5):275-278. PubMed ID: 33173380
[TBL] [Abstract][Full Text] [Related]
32. Preventing venous thromboembolism in oncology practice: Use of risk assessment and anticoagulation prophylaxis.
Martin KA; Molsberry R; Khan SS; Linder JA; Cameron KA; Benson A
Res Pract Thromb Haemost; 2020 Oct; 4(7):1211-1215. PubMed ID: 33134786
[TBL] [Abstract][Full Text] [Related]
33. Diagnosis and Treatment of Lower Extremity Venous Thromboembolism: A Review.
Chopard R; Albertsen IE; Piazza G
JAMA; 2020 Nov; 324(17):1765-1776. PubMed ID: 33141212
[TBL] [Abstract][Full Text] [Related]
34. Current use and safety of novel oral anticoagulants in adults with congenital heart disease: results of a nationwide analysis including more than 44 000 patients.
Freisinger E; Gerß J; Makowski L; Marschall U; Reinecke H; Baumgartner H; Koeppe J; Diller GP
Eur Heart J; 2020 Nov; 41(43):4168-4177. PubMed ID: 33184662
[TBL] [Abstract][Full Text] [Related]
35. Rivaroxaban Versus Warfarin in Patients with Mechanical Heart Valves: Open-Label, Proof-of-Concept trial-The RIWA study.
Duraes AR; de Souza Lima Bitar Y; Schonhofen IS; Travassos KSO; Pereira LV; Filho JAL; Neto MG; Junior RA; Roever L
Am J Cardiovasc Drugs; 2021 May; 21(3):363-371. PubMed ID: 33150497
[TBL] [Abstract][Full Text] [Related]
36. Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Two-year outcomes after the study closure.
Pengo V; Hoxha A; Andreoli L; Tincani A; Silvestri E; Prisco D; Fierro T; Gresele P; Cafolla A; De Micheli V; Ghirarduzzi A; Tosetto A; Falanga A; Martinelli I; Testa S; Barcellona D; Gerosa M; Denas G
J Thromb Haemost; 2021 Feb; 19(2):531-535. PubMed ID: 33128325
[TBL] [Abstract][Full Text] [Related]
37. Assessment of Outcomes Among Patients With Venous Thromboembolism With and Without Chronic Kidney Disease.
Goto S; Haas S; Ageno W; Goldhaber SZ; Turpie AGG; Weitz JI; Angchaisuksiri P; Nielsen JD; Kayani G; Farjat A; Schellong S; Bounameaux H; Mantovani LG; Prandoni P; Kakkar AK;
JAMA Netw Open; 2020 Oct; 3(10):e2022886. PubMed ID: 33112399
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of direct oral anticoagulants for secondary prevention of cancer associated thrombosis: a meta-analysis of randomized controlled trials.
Desai R; Koipallil GK; Thomas N; Mhaskar R; Visweshwar N; Laber D; Patel A; Jaglal M
Sci Rep; 2020 Nov; 10(1):18945. PubMed ID: 33144679
[TBL] [Abstract][Full Text] [Related]
39. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Rutjes AW; Porreca E; Candeloro M; Valeriani E; Di Nisio M
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD008500. PubMed ID: 33337539
[TBL] [Abstract][Full Text] [Related]
40. Prevention of venous thromboembolism in ambulatory patients with cancer.
Khorana AA; Cohen AT; Carrier M; Meyer G; Pabinger I; Kavan P; Wells P
ESMO Open; 2020 Nov; 5(6):e000948. PubMed ID: 33229505
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
